British F2G Biotech bags €24m
The European Investment Bank (EIB) has lent antiinfectives company F2G Biotech Ltd €24m for antifungal research and innovation under the InnovFin Infectious Diseases Finance Facility (IDFF).
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
Entries by Thomas Gabrielczyk
Sugar replacement slows cancer growth
Researchers at Cancer UK have slowed down tumour growth by simply feeding mice that carry human tumour xenografts with mannose instead of glucose.
Vertical integration: time is money
Financial pressure on Big Pharma and biotechs increases the need for drug developers to outsource their development and manufacturing capabilities. The CDMO and CRO sector, which is further consolidating through M&A, looks well set for continued growth. As developers have to balance the need to reduce their development risk with time to market or – for biotechs – time to next financing, contract manufacturing and contract research companies clearly favour offering fully integrated services.
Epigenetic drugs can increase tumour malignancy
Researchers at IRB Barcelona report that tumours may become more aggressive following treatment with drugs that inhibit epigenetic factors.
Forbion leads €40m financing in Inflazome Ltd
Inflammosome inhibitor specialist Inflazome Ltd has raised €40m in a Series B financing led by Forbion with co-investors Longitude Capital, Novartis Venture Fund and Fountain Healthcare Partners.
EC advisors call for update of GM legislation
The EU Commission’s Chief Scientific Advisors urge the Commission to revise the EU’s GMO Directive in order to harness gene editing.
Boehringer and Epizyme enter US$300m deal
Boehringer Ingelheim and Epizyme, Inc. will collaborate in the field of small molecule cancer drugs that target unaddressed epigenetic targets within the helicase and histone acetyltransferase families.
Breakthrough in restless legs syndrome
Researchers at University of Göttingen, Germany, have identified nerve excitability of motor nerve cells trigger restless legs syndrome.
SOBI and AstraZeneca in US$2bn+ deal on RSV antibodies
AstraZeneca plc has sold US rights to its off-patent blockbuster drug Synagis (palivizumab) and a 50% share on future earnings of its Phase II RSV-prophylactic follow-on antibody MEDI8897 to Swedish Orphan Biovitrum AB.
Amal bags €21.2m financing
Swiss Amal Therapeutics S.A. (Geneva) has raised €21.2m in a series B follow-up financing.